A Regulatory Perspective on Essential Considerations in Design and Analysis of Subgroups When Correctly Classified

REFERENCES

• Brannath , W. , Zuber , E. , Branson , M. , Bretz , F. , Gallo , P. , Posch , M. , Racine-Poon , A. ( 2009 ). Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology . Statistics in Medicine 28 : 1445 – 1463 .
   PubMed Web of Science ®Google Scholar
• Brilinta label. ( 2013 ). Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/ 2013/022433s006lbl.pdf
   Google Scholar
• Brookes , S. T. , Whitely , E. , Egger , M. , Smith , G. D. , Mulheran , P. A. , Peters , T. J. ( 2004 ). Subgroup analyses in randomized trials: Risks of subgroup-specific analyses; power and sample size for the interaction test . Journal of Clinical Epidemiology 57 : 229 – 236 .
   PubMed Web of Science ®Google Scholar
• Cold comfort. ( 2002 ). Lancet Infectious Diseases 2 : 385 .
   PubMedGoogle Scholar
• Cui , L. , Hung , H. M. , Wang , S. J. , Tsong , Y. ( 2002 ). Issues related to subgroup analysis in clinical trials . Journal of Biopharmaceutical Statistics 12 : 347 – 358 .
   PubMedGoogle Scholar
• Diovan label. ( 2002 ). Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/ 2002/20665s16lbl.pdf
   Google Scholar
• Erbitux label. ( 2012 ). Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/ 2012/125084s225lbl.pdf
   Google Scholar
• Food and Drug Administration . ( 2013 ). Health Human Services, Code of Federal Regulation, 21CFR314.126. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=314.126
   Google Scholar
• Food and Drug Administration. ( 1998 ). U.S. Food and Drug Administration Guidance for Industry: Providing clinical evidence of effectiveness for human drug and biological products. Available at: http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/ucm078749.pdf
   Google Scholar
• Food and Drug Administration . ( 2012 ). Draft guidance for industry: Enrichment strategies for clinical trials to support approval of human drugs and biological products. Available at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatory information/guidances/ucm332181.pdf (released December 14, 2012, for public comments) .
   Google Scholar
• Freidlin , B. , Simon , R. ( 2005 ). Adaptive signature design: An adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients . Clinical Cancer Research 11 : 7872 – 7878 .
   PubMed Web of Science ®Google Scholar
• Gregson , B. A. , Broderick , J. P. , Auer , L. M. , Batjer , H. , Chen , X. C. , Juvela , S. , Morgenstern , L. B. , Pantazis , G. C. , Teernstra , O. P. M. , Wang , W. Z. , Zuccarello , M. , Mendelow , A. D. ( 2012 ). Individual patient data subgroup meta-analysis of surgery for spontaneous supratentorial intracerebral hemorrhage . Stroke 43 : 1496 – 1504 .
   PubMed Web of Science ®Google Scholar
• Hughes , S. , Hughes , A. , Brothers , C. , Spreen , W. , Thorborn , D. , CNA106030 Study team. ( 2008 ). PREDICT-1: The first powered prospective trial of pharmacogenetic screening to reduce drug adverse events . Pharmaceutical Statistics 7 : 121 – 129 .
   PubMed Web of Science ®Google Scholar
• Hung , H. M. J. , Wang , S. J. , O'Neill , R. ( 2010 ). Consideration of regional difference in design and analysis of multi-regional trials . Pharmaceutical Statistics 9 : 173 – 178 .
   PubMed Web of Science ®Google Scholar
• International Conference on Harmonization. ( 1998a ). International Conference on Harmonization (ICH) guidance, E9 Statistical Principles for Clinical Trials (ICH E9 guidance). February. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline.pdf
   Google Scholar
• International Conference on Harmonization. ( 1998b ). International Conference on Harmonization (ICH) guidance, E5 (R1) Ethnic factors in the acceptability of foreign clinical data. February. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ ICH_Products/Guidelines/Efficacy/E5_R1/Step4/E5_R1_Guideline.pdf
   Google Scholar
• Johnston , S. , Pippen , J. , Pivot , X. , Lichinitser , M. , Sadeghi , S. , Dieras , V. , Gomez , H. L. , Romieu , G. , Manikhas , A. , Kennedy , M. J. , Press , M. F. , Malzman , J. , Florance , A. , O'Rourke , L. , Oliva , C. , Stein , S. , Pegram , M. ( 2009 ). Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer . Journal of Clinical Oncology 27 ( 33 ): 5538 – 5546 .
   PubMed Web of Science ®Google Scholar
• Louis , A. , Cleland , J. G. F. , Crabbe , S. , Ford , S. , Thackray , S. , Houghton , T. , Clark , A. ( 2001 ). Clinical trials update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the scientific sessions of the American College of Cardiology, 2001 . European Journal of Heart Failure 3 : 381 – 387 .
   PubMed Web of Science ®Google Scholar
• Martinez , F. J. , Grossman , R. F. , Zadeikis , N. , Fisher , A. C. , Walker , K. , Ambruzs , M. E. , Tennenberg , A. M. ( 2005 ). Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: The role of levofloxacin 750 mg . European Respiratory Journal 25 : 1001 – 1009 .
   PubMed Web of Science ®Google Scholar
• Mehta , C. , Gao , P. , Bhatt , D. L. , Harrington , R. A. , Skerjanec , S. , Ware , J. H. ( 2009 ). Optimizing trial design: Sequential, adaptive, and enrichment strategies . Circulation 119 : 597 – 605 .
   PubMed Web of Science ®Google Scholar
• Millen , B. A. , Dmitrienko , A. , Ruberg , S. , Shen , L. ( 2012 ). A statistical framework for decision making in confirmatory multipopulation tailoring clinical trials . Drug Information Journal . doi: 10.1177/0092861512454116 .
   Web of Science ®Google Scholar
• McNeil , C. ( 2008 ). K-Ras mutations are changing practice in advanced colorectal cancer . Journal of National Cancer Institute 100 ( 23 ): 1667 – 1669 .
   PubMed Web of Science ®Google Scholar
• National Institutes of Health . ( 1994 ). NIH guidelines on the inclusion of women and minorities as subjects in clinical research . Federal Register 59 : 14508 – 14513 .
   Google Scholar
• Oxman , A. , Guyatt , G. , Green , L. , Craig , J. , Walter , S. , Cook , D. ( 2002 ). When to believe a subgroup analysis . In: Guyatt , G. , Rennie , D. , eds. Users’ guides to the medical literature. A manual for evidence-based clinical practice . Chicago , IL : AMA Press , pp. 553 – 565 .
   Google Scholar
• President signs FDA user fee bill as industry begins watching for implementation issues. ( 2012 ). Sidley.com. Available at: http://www.sidley.com/President-Signs-FDA-User-Fee-Bill-as-Industry-Begins-Watching-for-Implementation-Issues-07-09-2012
   Google Scholar
• Ranieri , V. M. , Thompson , B. T. , Barie , P. S. , Dhainaut , J. F. , Douglas , I. S. , Finfer , S. , Gardlund , B. , Marshall , J. C. , Rhodes , A. , Artigas , A. , Payen , D. , Tenhunen , J. , Al-Khalidi , H. R. , Thompson , V. , Janes , J. , Macias , W. L. , Vangerow , B. , Williams , M. D. , for the PROWLESS-SHOCK Study Group. ( 2012 ). Drotrecogin Alfa (Activated) in adult with septic shock . New England Journal of Medicine 366 : 2055 – 2064 .
   PubMed Web of Science ®Google Scholar
• Rothman , M. D. , Zhang , J. J. , Lu , L. , Fleming , T. R. ( 2012 ). Testing a prespecified subgroup and the intent-to-treat population . Drug Information Journal 46 : 175 – 179 .
   PubMed Web of Science ®Google Scholar
• Rothwell , P. ( 2005 ). Subgroup analysis in randomized controlled trials: Importance, indications, and interpretation . Lancet 365 : 176 – 186 .
   PubMed Web of Science ®Google Scholar
• Simon , R. , Wang , S. J. ( 2006 ). Use of genomic signatures in therapeutics development in oncology and other diseases. Advance online publication, January 17, 2006 . Pharmacogenomics Journal 6 : 166 – 173 .
   PubMed Web of Science ®Google Scholar
• Smith , P. G. , Day , N. E. ( 1984 ). The design of case-control studies: The influence of confounding and interaction effects . International Journal of Epidemiology 13 : 356 – 365 .
   PubMed Web of Science ®Google Scholar
• Sun , X. , Briel , M. , Busse , J. W. , You , J. J. , Akl , E. A. , Mejza , F. , Bala , M. M. , Bassler , D. , Mertz , D. , Diaz-Granados , N. , Vandvik , P. O. , Malaga , G. , Srinathan , S. K. , Dahm , P. , Johnston , B. C. , Alonso-Coello , P. , Hassouneh , B. , Walter , S.D. , Heels-Ansdell , D. , Bhatnagar , N. , Altman , D. G. , Guyatt , G. H. ( 2012 ). Credibility of claims of subgroup effects in randomized controlled trials: systematic review . British Medical Journal 15 : 344 . doi: 10.1136/bmj.e1553.
   Google Scholar
• Schultz , K. F. , Grimes , D. A. ( 2005 ). Multiplicity in randomized controlled trials II: Subgroup and interim analyses . Lancet 365 : 1657 – 1661 .
   PubMed Web of Science ®Google Scholar
• Tarceva label . ( 2013 ). Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/ 2013/021743s018lbl.pdf
   Google Scholar
• Xigris label. ( 2007 ). Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/ 2007/125029s080LBL.pdf
   Google Scholar
• Wang , S. J. ( 2007 ). Biomarker as a classifier in pharmacogenomics clinical trials: A tribute to 30th anniversary of PSI . Pharmaceutical Statistics 6 : 283 – 296 .
   PubMed Web of Science ®Google Scholar
• Wang , S. J. , Cohen , N. , Katz , D. A. , Ruano , G. , Shaw , P. , Spear , B. ( 2006 ). Retrospective validation of genomic biomarkers—What are the questions, challenges and strategies for developing useful relationships to clinical outcomes—Workshop summary . Pharmacogenomics Journal 6 : 82 – 88 .
   PubMed Web of Science ®Google Scholar
• Wang , S. J. , Hung , H. M. J. ( 2012 ). Ethnic sensitive or molecular sensitive beyond all regions being equal in multiregional clinical trials . Journal of Biopharmaceutical Statistics 22 : 879 – 893 .
   PubMed Web of Science ®Google Scholar
• Wang , S. J. , Hung , H. M. J. , O'Neill , R. T. ( 2009 ). Adaptive patient enrichment designs in therapeutic trials . Biometrical Journal 51 ( 2 ): 358 – 374 .
   PubMed Web of Science ®Google Scholar
• Wang , S. J. , O'Neill , R. T. , Hung , H. M. J. ( 2007 ). Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset . Pharmaceutical Statistics 6 : 227 – 244 .
   PubMed Web of Science ®Google Scholar
• Wang , S. J. , O'Neill , R. T. , Hung , H. M. J. ( 2010 ). Some statistical considerations in evaluating pharmacogenomics confirmatory clinical trials . Clinical Trials 7 : 525 – 536 .
   PubMed Web of Science ®Google Scholar
• Wedel , H. , DeMets , D. , Deedwania , P. , Fagerberg , B. , Goldstein , S. , Gottlieb , S. , Hjalmarson , A. , Kjekshus , J. , Waagstein , F. , Wikstrand , J. , on belahf of the MERIT-HF Study Group. (2001). Challenges of subgroup analyses in multinational clinical trials: Experiences from the MERIT-HF trial. American Heart Journal 142:502–511.
   PubMed Web of Science ®Google Scholar
• Yusuf , S. , Wittes , J. , Probstfield , J. , Tyroler , H. A. ( 1991 ). Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. Special communication . Journal of the American Medical Association 266 ( 1 ): 93 – 98 .
   Google Scholar
• This article not subject to US copyright law.
   Google Scholar
• Color versions of one or more of the figures in the article can be found online at www.tandfonline.com/lbps.
   Google Scholar